|
|
|
|
|
|
|
|
open access
Published 18 April 2016
full text
Ongoing research
SOLO-1 and SOLO-2 are multicenter, double-blind
studies of olaparib 300 mg bid versus placebo in patients with
high-grade serous or endometrioid ovarian, fallopian tube, or primary
peritoneal cancer. Both SOLO-1 and SOLO-2 have primary outcomes of
progression-free survival by response evaluation criteria in solid
tumors (RECIST) criteria in olaparib 300 mg twice daily monotherapy
maintenance compared to placebo. The study population of SOLO-1 is
BRCA-mutated high-risk advanced ovarian cancer patients who achieved
complete or partial response with first-line platinum chemotherapy,
whereas the population of SOLO-2 is BRCA-mutated relapsed ovarian cancer
patients who achieved complete or partial response with platinum
chemotherapy. In SOLO-1, the patients will receive olaparib versus
placebo for up to 2 years or until objective response by RECIST criteria
and the treatment may continue beyond 2 years for those with stable
disease or progression. Patients in SOLO-2 will receive olaparib versus
placebo until progression by RECIST criteria or as long as they are
benefiting from treatment and do not meet other criteria for
discontinuation.16,17
The current FDA approval for olaparib is for
patients who have received three or more prior lines of chemotherapy. A
recent study by Marques et al investigated whether the administration of
chemotherapy affected intratumoral PARP expression. Tissue samples were
obtained from three cohorts, totaling 313 high-grade serous ovarian
cancers. PARP1 expression was measured by immunohistochemistry and
Western blot protein analysis. Samples from patients who had undergone
chemotherapy had significantly lower protein expression than
chemotherapy-naïve tumor samples. Of 15 samples from patients which had
both pre- and postchemotherapy (carboplatin and paclitaxel), six had
absent PARP1 expression and eight had reduced PARP1 levels
postchemotherapy. The clinical significance of this change in PARP1
expression is unknown; however, the dynamic interaction of PARP1 and
chemotherapy should be taken into consideration in future studies.18 It is possible that the use of olaparib before exposure to multiple lines of chemotherapy would be a more effective use.
Conclusion
Olaparib is a well-tolerated oral chemotherapeutic
agent that has FDA approval for the treatment of ovarian cancer in
patients with germline BRCA 1/2 mutations who have received three or
more prior lines of chemotherapy. In the future, development of assays
for function of homologous recombination may help to identify patients
without a germline BRCA 1/2 mutation who would also benefit from
treatment with olaparib. Further studies will also help delineate the
optimal timing and setting of olaparib administration.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.